Body--Internal Uses

Glutathione is our body's main antioxidant, and no cell can survive without it.

**** "An experimental treatment for Lou Gehrig’s disease won fast track and orphan drug designations from the Food and Drug Administration, potentially speeding ..."

"The treatment groups received a single intraperitoneal administration of... 0.5 ml tetrachlorodecaoxide (TCDO)"

"chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. ... including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration." "WF10, .. The approximately 12.3 pH of this formulation may be problematic for some forms of administration to physiological systems." "Effective dosages may be estimated initially from in vitro assays. For example, an initial dosage for use in animals may be formulated to achieve a circulating blood or serum concentration of active compound that is at or above an IC50 of the particular compound as measured in an in vitro assay." "WF10 treatment resulted in nonspecific toxicity at concentrations of 50 μM and higher, whereas TJ001 did not result in nonspecific toxicity until concentrations of 200 μM and higher."

"chemical decellularization treatment in 4% aqueous sodium chlorite" "These results open new avenues for the use of DECM samples as the replacement of wide bone tissue defects."

In South America, a toxic chemical is being touted as a miracle cure for Covid-19. How did the mistaken belief in its powers take hold?

{Additional info at https://www.semanticscholar.org/paper/Comparative-study-on-the-effects-of-chlorite-oxygen/626aa09e2804f400264ed3879e7170095af242c8 }

Tetrachlorodecaoxygen (TCDO) therapy of acute radiation syndrome was tested for a possible influence on the development of X-ray-induced malignancies. BD IX rat...

The influence of tetrachlorodecaoxide (TCDO) on the chronic radiation damage after local irradiation of the rat colon was examined when given at different times and at different doses. A tetrachlorodecaoxide treatment before the acute period resulted in an extension of the latency period. When tetra …

****!!!!***

"WF-10 did not influence early steps of target-cell killing, but impaired the ability of CTLs to detach from the initial target cell and to move to a second target cell. This reduced serial killing was accompanied by stronger enrichment of the adhesion molecule LFA-1 in the cytolytic immune synapse. LFA-1 clustering requires activation of the actin-bundling protein L-plastin and was accordingly diminished in L-plastin knockdown cells. Interestingly, WF-10 likely acts through regulating L-plastin: (I) It induced L-plastin activation through phosphorylation leading to enhanced LFA-1-mediated cell adhesion, and, importantly, (II) WF-10 lost its influence on target-cell killing in L-plastin knockdown cells. Finally, we demonstrate that WF-10 can improve immunosuppression by conventional drugs. Thus, while cyclosporine A alone had no significant effect on cytotoxicity of CTLs, a combination of cyclosporine A and WF-10 blocked target-cell killing synergistically. Together, our findings suggest that WF-10 – either alone or in combination with conventional immunosuppressive drugs – may be efficient to control progression of diseases, in which CTLs are crucially involved."

"WF10 is a chlorite-based drug that modulates macrophages functional states and can be safely administered to humans. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory rea …"

2000 "This model has been utilized in the drug development of WF10, a novel macrophage-targeted drug, currently in advanced clinical testing for the treatment of HIV disease."

{NP001, WF-10} {Note: This article may have some inaccuracies}

"Neuraltus won't release data from the Phase II trial of NP-001 until later this year, possibly next month. The drug last summer won Food and Drug Administration fast-track and orphan drug designations, which potentially could accelerate the clinical trial process by waiving FDA fees and providing tax breaks for the company's clinical trial costs."

******!!!!**** "NP001 has been reported to reorient toxic inflammatory macrophages that invade the central nervous system into normal, protective ones"

"This is a phase I, placebo-controlled, single ascending dose safety and tolerability study of NP001 in patients with ALS. NP001 is a novel regulator of inflammatory macrophages and monocytes. As ALS progression is thought to be related to neuroinflammation, ..."

"On 19 June 2013, orphan designation (EU/3/13/1139) was granted by the European Commission to Shore Limited, United Kingdom, for sodium chlorite (also known as NP001) for the treatment of amyotrophic lateral sclerosis." {Other listed sponsor: FGK Representative Services GmbH, Germany}